Wynnewood, Pennsylvania Clinical Research Trials

Found 103 clinical trials

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)

Mucosal-dominant pemphigus vulgaris (mPV) is a B-cell mediated autoimmune disorder in which painful blisters are formed on the mucosal membrane, including the mouth, nose, throat, eyelids, anus, and genitals. This phase 1 study is being conducted to find the maximum tolerated dose and optimal fractionated infusion schedule of an investigational …

University of Pennsylvania

(5.1 away) Contact site

0 views
19 Feb, 2024
1 location

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients.

SARS

cancer

nasal swab

oximetry

acute respiratory syndrome (sars)

Temple University Hospital

(6.8 away) Contact site

0 views
19 Feb, 2024
+1 other locations

Multi-country trial
Phase 4
For adults
Recruiting in 100s
Interventional Study
all
Recruiting

Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled. The treating neurologist must make an …

Jefferson University Hospitals, Thomas Jefferson University

(7.0 away) Contact site

0 views
19 Feb, 2024
+30 other locations

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.

coronavirus infection

dyspnea

cough

fever

pao2

Temple University

(6.8 away) Contact site